Abstract Book

S769

ESTRO 37

Purpose or Objective The recurrence rates was high in esophageal squamous cell carcinoma (ESCC) patients after surgery. This study was arm to retrospectively analysized of factors on postoperative recurrence in patients of stage pT1-3N0M0 thoracic ESCC after radical resection. Material and Methods From Jan 2008 to Dec 2012, there were 488 thoracic ESCC patients which had treated with two-field R0 resection, stage pT1-3N0M0, without neoadjuvant or adjuvant radiotherapy and/or chemotherapy, survival time 3 months or more were erolled in this study. Factors on postoperative recurrence for those patients was anlysized with SPSS22.0 software. o-fareast-font- family: 宋体 ;esophageal squamous cell carcinoma (ESCC) patients after surgery. This study was arm to retrospectively analysized of factors on postoperative recurrence in patients of stage pT1-3N0M0 thoracic ESCC after radical resection. Results The end date of follow-up was Dec 2016. The total recurrence rate for all patients was 36.9% (180/488); the rates of locoregional recurrence (LR), distant metastasis (DM) and LR add DM were 21.5%(105/488), 6.8% (33/488) and 8.6% (42/488), respectively. Logistic unvariate and multivariate analysis showed that, tumor site and stage pT were independent factors for total recurrence, LR and DM in pT1-3N0M0 ESCC patients after R0 resection. The rates of total recurrence, LR and DM were 54.1%, 44.3%, 24.6% in upper-thoracic –segment, 37.2%, 30.5%, 14.8% in middle-thoracic-segment, 22.9%, 18.1%, 10.8% in low- thoracic-segment ESCC. The rates of total recurrence, LR and DM were 15.7%, 11.8%, 4.9% for pT1, 41.3% , 34.9%, 9.4% for pT2, and 43.1%, 35.0%, 14.4% for pT3 patients, respectively. Conclusion umor site and stage pT were most important factors for postoperative recurrence in pT1-3N0M0 ESCC patients; and its results probably be use to direct target of postoperative adjuvant radiotherapy in those patients. EP-1413 clinical efficacy between single and dual- agent chemoradiotherapy in esophageal carcinoma J. Li 1 , D. Xiaobo 2 1 Mian Yang Central Hospital, Department of Oncology, Mian Yang city- Fucheng Distri, China 2 Mian Yang Central Hospital, Department of Oncology, No. 12- lane- alarm street- Fucheng District- Sichuan- Mianyang, China Purpose or Objective In China, single-agent concurrent chemoradiotherapy is commonly used to treat patients with unresectable esophageal squamous cell carcinoma, those who are older, or those who have reduced food intake. However, it remains unknown whether single-agent and dual-agent concurrent chemoradiotherapy are equally clinically effective. The main purpose of this retrospective study was to compare the clinical efficacies of single-agent and dual-agent concurrent chemoradiotherapy in patients with unresectable esophageal squamous cell carcinoma. Material and Methods This study enrolled 133 patients who received definitive concurrent chemoradiotherapy for locally advanced unresectable esophageal squamous carcinoma at 10 hospitals between 2010 and 2015. Patients who were treated with definitive concurrent chemoradiotherapy with or without adjuvant chemotherapy were included in the study. Patients were categorized into different treatment arms based on treatment with single-agent or double-agent chemoradiation. Results In this study, 81 (60.9%) and 52 patients (39.1%) received single-agent and dual-agent combination chemoradio- therapy, respectively. The 5-year progression-free

in 6 patients (33%) who were treated with Carb/TAX and 4 patients (15%) who were treated with CDDP/5FU (p=0.273). Patients treated with CDDP/5FU developed significant more cumulative hematologic III° (CTCAE) toxicities (58% vs 20%; p=0.010) than patients treated with Carb/TAX. In contrast to that, there was no significant difference for OS and DFS between treatment groups. Conclusion While there was no difference for OS and DFS, nCRT with CDDP/5FU is associated with, significant more hematologic III°- toxicities compared nCRT with Carb/TAX. Therefore, nCRT with Carb/TAX should be the current treatment of choice for patients with locally advanced SCC. EP-1411 Comparison between radiochemotherapy, and other modalities in locally advanced esophageal cancer D. Scepanovic 1 , I. Zavacka 1 , A. Masarykova 1 , A. Hanicova 1 , M. Dzongov 1 , M. Pobijakova 1 , Z. Dolinska 1 1 National Cancer Institute, Radiation Oncology, Bratislava, Slovakia Purpose or Objective Background . - Treatment of locally advanced esophageal carcinoma has been changed for the last 15 years. The low cure rates after external beam radiotherapy (EBRT) alone prompted the inclusion of systemic chemotherapy (CT) in multimodality treatment regimens, to control distant micrometastatic disease and enhance local radiation effects. However, it is still a highly lethal malignancy. The aim of our work was to show whether the addition of surgery or intraluminal brachytherapy (ILBT) after radiochemotherapy could improve the overall survival of these patients. Material and Methods Between 2008 and 2015, 70 patients (pts) with locally advanced esophageal cancer received radiation therapy (RT) with/without CT. Thirty one pts had EBRT with/without CT. Nineteen pts had surgery six weeks after completion of RT/CT and 20 pts combined EBRT/CT followed by intraluminal brachytherapy (ILBT). In the neoadjuvant approach total doses that range between 30 and 50Gy with concomitant CT of cisplatin and fluorouracil have been applied. On the average a week after the EBRT a median total dose of 10Gy ILBT was given in 2 fractions. Results During the median follow up of 16 months (range, 4-108) for all pts, 5 pts were alive in group of EBRT with/without CT and 6 pts with neoadjuvant settings. The overall cumulative survival rate was 17% at 3 years for whole group of pts. The 3-year overall survival (OS) rate for EBRT with/without CT group and neoadjuvant group was 16% and 15%, respectively (chi-square statistic=0.0072, p-value=.932256, the result is not significant at p < .05). However, pts who were alive, showed a long-term survival of longer than 3 years in a neoadjuvant group of pts. Conclusion Our analysis suggested, although there was no statistically significant difference between the two groups of our patients in terms OS, patients who had surgery or ILBT after EBRT with / without CT lived longer. EP-1412 The pattern of postoperative recurrence in patients of stage pN0 ESCC after two-field esophagectomy Y.X. Wang 1 , S.L. Dong 1 , M. He 2 , J. Li 1 , J. Yang 1 , Z. Qi 2 , X.Y. Qiao 1 1 The Fourth Hospital of Hebei Medical University, Department of Radiation Oncology, Shijiazhuang, China 2 The Fourth Hospital of Hebei Medical University, Department of thoracic surgery, Shijiazhuang, China